Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × dinutuximab × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡